



Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry

journal homepage: <http://www.elsevier.com/locate/ejmech>

Review article

Therapeutic potential of songorine, a diterpenoid alkaloid of the genus *Aconitum*

Haroon Khan ^a, Seyed Mohammad Nabavi ^b, Antoni Sureda ^c, Nikolay Mehterov ^{d, e, f}, Diana Gulei ^g, Ioana Berindan-Neagoe ^{g, h, i}, Hiroaki Taniguchi ^j, Atanas G. Atanasov ^{j, k, *}

^a Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan^b Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box 19395-5487, Tehran, Iran^c Grup de Nutrició Comunitària i Estrès Oxidatiu (IUNICS) and CIBEROBN (Physiopathology of Obesity and Nutrition), Universitat de les Illes Balears, Palma de Mallorca, Spain^d Department of Medical Biology, Faculty of Medicine, Medical University-Plovdiv, 15-A Vassil Aprilov Blvd., Plovdiv 4000, Bulgaria^e Technological Center for Emergency Medicine, 15-A Vassil Aprilov Blvd., Plovdiv 4000, Bulgaria^f Center of Plant Systems Biology and Biotechnology, 139 Ruseki Blvd., Plovdiv 4000, Bulgaria^g MEDFUTURE -Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 23 Marinescu Street, 400337, Romania^h Research Center of Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 23 Marinescu Street, 400337 Cluj-Napoca, Romaniaⁱ Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Republicii 34 Street, 400015 Cluj-Napoca, Romania^j Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, 05-552 Jastrzebiec, Poland^k Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria

ARTICLE INFO

Article history:

Received 10 August 2017

Received in revised form

5 October 2017

Accepted 24 October 2017

Available online xxx

Keywords:

Songorine

Aconitum

Aconitine alkaloid

Multiple pharmacological effects

ABSTRACT

Alkaloids are well-studied secondary metabolites, with recent preclinical studies evidencing that many of them exhibit anti-cancer, anti-depressant, anti-nociceptive, anti-inflammatory, anti-pyretic, anti-platelet, anti-oxidant, and anti-bacterial properties. *Aconitum* is a genus rich of diverse alkaloids. More than 450 alkaloids have been identified in a variety of species. Songorine is a C₂₀ diterpenoid alkaloid and 12-keto analog of napelline, isolated from *Aconitum soongaricum* and was associated with a heterogeneous panel of biological functions. However, the bioactivity profile of this natural product has not been reviewed up to now. The present manuscript aims to summarize the most important biological activities associated with songorine administration in preclinical models. The most significant data found in the scientific literature were evaluated in order to summarize the potential clinical utility of songorine in a diverse spectrum of pathologies and conditions. Songorine and its derivatives have many pharmacological effects including anti-arrhythmic, anti-cardiac-fibrillation, excitation of synaptic transmission, anxiolytic effects, anti-nociceptive, anti-inflammatory, anti-arthritis effects, and a regenerative effect in a skin excision wound animal model. Despite its outstanding pharmacotherapeutic potential, songorine has never been tested in clinical trials. Therefore, further evaluation is required to better evaluate its clinical utility.

© 2017 Elsevier Masson SAS. All rights reserved.

Contents

1. Introduction	00
2. Antiarrhythmic activity of songorine in <i>in vivo</i> models of experimental arrhythmia	00
3. Central nervous system (CNS) stimulatory effects upon songorine administration	00
4. Songorine is associated with analgesic effects and also anti-inflammatory properties	00
5. Mechanisms behind the increased wound healing properties of songorine (regenerative properties)	00

* Corresponding author. Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, 05-552 Jastrzebiec, Poland.

E-mail address: a.atanasov.mailbox@gmail.com (A.G. Atanasov).

6. In vivo pharmacokinetic studies involving songorine administration	00
7. Aconite detoxification and safe administration of songorine	00
8. Conclusions and future prospects	00
Conflicts of interest	00
Acknowledgments	00
References	00

Abbreviations

ED ₅₀	Median effective dose
LD ₅₀	Median lethal dose
AAI	Antiarrhythmic index
CNS	Central nervous system
GABAA	γ-Aminobutyric acid A
NSAIDS	Nonsteroidal anti-inflammatory drugs
PI3K	Phosphoinositide 3-kinase
ERK1/2	Extracellular signal-regulated protein kinases 1 and 2
JNK	c-Jun N-terminal kinase
NF-κB/IKK	Nuclear factor-κB/IκB kinase
TNF-α	Tumor necrosis factor alpha
IFN-γ	Interferon gamma
IL	Interleukin
SOD	Superoxide dismutase
GPx	Glutathione peroxidase
MMPs	Metalloproteinases

1. Introduction

Phytopharmaceuticals have played an important role in the history of medicine and, to this day, they are considered an integral part of our health care system [1–4]. Despite the great advances of modern therapeutics, phytopharmaceuticals continue to play crucial role in the treatment of various disorders [5,6]. Additionally, many modern drug classes must deal with problems related to efficacy and therapeutic resistance [3,7–9]. Natural compounds could therefore represent a viable option for developing therapies due to their vast chemical diversity [10].

Alkaloids are among the most widely distributed plant-derived secondary metabolites [11,12]. Several alkaloids and their derivatives have been used clinically to treat a variety of medical disorders. Similarly, numerous alkaloids have marked preclinical effects including anti-platelet [3], anti-cancer [13], anti-inflammatory [6] antibacterial [14], anti-depressant [15], and anti-oxidant properties [16]. However, further evaluation is required to make a smooth transition to clinical applications.

Aconitum is a genus member of the Ranunculaceae family very rich in alkaloids. In this sense, more than 450 alkaloids have been identified in various *Aconitum* species [17]. Also, over 40 alkaloids have been described in *Aconitum carmichaelii* alone [18]. Songorine is an alkaloid mainly present in *Aconitum soongaricum* L. which absolute configuration was first solved by Okamoto et al., in 1965 [19,20]. In a later study, songorine was also found in the mother and lateral roots of *Aconitum carmichaelii* Debx, but not in *Aconitum kusnezoffii* Reichb [21]. It is a C₂₀ diterpenoid alkaloid and a 12-keto analog of napelline [22]. Members of the *Aconitum* family plants possess properties amendable to the treatment of pain, inflammatory processes, coldness of extremities, and metabolic

dysfunction [22,23]. In fact, in the traditional Chinese and Japanese medicine diverse preparations from *Aconitum* roots have been widely used to treat many disorders [24,25]. This review focuses on the diverse biological activities of songorine (Fig. 1) and its prospects for future clinical applications.

2. Antiarrhythmic activity of songorine in *in vivo* models of experimental arrhythmia

Dzhakhangirov et al. (1997) studied the antiarrhythmic properties of a large number of diterpene alkaloids, including songorine [26]. In the performed animal studies, antiarrhythmic properties were tested in the models of aconitine arrhythmia in anesthetized rats and of irreversible cardiac fibrillation in alert mice. Songorine displayed significant anti-arrhythmic effects both in rats and mice. The median effective dose (ED₅₀) was 7.3 mg/kg while the median lethal dose (LD₅₀) was 142.5 mg/kg in rats. Marked anticardiac-fibrillation action was elicited in mice with ED₅₀ of 25 mg/kg and LD₅₀ of 480 mg/kg. In a study using isolated rat cardiomyocytes it has been reported that the treatment with ryanodine induces an increase in the intracellular concentrations of calcium (Ca²⁺) from the sarcoplasmic reticulum [27]. Treatment with songorine blocks the liberation of Ca²⁺ in cardiomyocytes and this, can be associated with the antiarrhythmic effects of the compound. Various songorine analogues also produced a wide range of diverse effects. Shakhidoyatova et al. (2001) synthesized a series of songorine derivatives and evaluated their antiarrhythmic properties in the aconitine-induced arrhythmia model in rats [28]. It was evidenced that mono-aromatic ester substitution potentiates the effects of songorine, but instead, free hydroxyl groups are crucial for the antiarrhythmic effects since benzoylation of these groups results in the loss of the activity [26]. Songorine and its derivatives exhibit significant antiarrhythmic effects and favorable safety profile (Scheme 1 and Table 1).

3. Central nervous system (CNS) stimulatory effects upon songorine administration

Songorine has been reported to exert stimulatory effects in *in vivo* studies that has been associated with the dopaminergic system. Ameri (1998) studied the effect of alkaloids on synaptic transmission in rat hippocampus [22]. At a concentration of 10–100 μM, songorine caused excitatory synaptic transmission in a dose dependent manner. Dopamine D1 receptor antagonists do not antagonize this transmission. However, sulpiride (0.1 μM) and haloperidol (10 μM), both selective D₂ receptor blockers, inhibit this synaptic excitation. Stimulation of the CNS by alkaloids is well established [29,30]. A stereotypic head rocking motion in cats that were administrated 50–100 mg/kg of songorine has been described [22,31]. Similarly, pretreatment with songorine *in vivo* blocked the sedative-like action of bulbocapnine, a dopamine receptor antagonist [22]. Zhao et al. (2003) have studied songorine's impact in rat hippocampal neurotransmission in order to shed light on the mechanisms governing excitatory synaptic transmission [17].





Fig. 1. Biological effects of songorine.



$\text{Songorine} = \text{R}_1 = \text{R}_2 = \text{H}$
 1,15-O-diacetylsongorine = $\text{R}_1 = \text{R}_2 = \text{Ac}$
 Dibenzoylsongorine = $\text{R}_1 = \text{R}_2 = \text{Bz}$
 1-O-acetylsongorine = $\text{R}_1 = \text{Ac}, \text{R}_2 = \text{H}$
 1-O-benzoylsongorine = $\text{R}_1 = \text{Bz}, \text{R}_2 = \text{H}$

Scheme 1. Chemical structure of songorine and selected songorine analogues.

Table 1

Antiarhythmic activity of the synthesized compounds on the aconitine-induced arrhythmia model in rats [28].

Compound	LD_{50} (mg/kg)	ED_{50} (mg/kg)	AAI = $\text{ED}_{50}/\text{LD}_{50}$
Songorine	142	7.3	19
1,15-O-diacetylsongorine	131	18	7.3
1-O-acetylsongorine	150	15	10
1-O-benzoylsongorine	41	0.38	107.9

Profound inhibition of γ -aminobutyric acid A (GABA A) in rat hippocampal neurons was observed, which provided the mechanistic evidence for songorine as a GABA A receptor antagonist in the brain of rats.

Anxiolytic effect upon pretreatment with songorine (0.25 mg/kg) was also reported in mice, with the effect of the compound even exceeded the action of the positive control phenazepam. However, songorine was devoid of sedative effects increasing the approaches to drinkers, locomotor activity and rearings, in contrast to phenazepam which significantly decreased all these parameters respect to the control group [32].

4. Songorine is associated with analgesic effects and also anti-inflammatory properties

The analgesic effects of songorine alkaloid can derive from the potentiation of central and peripheral mechanism. Nesterova et al.

(2014) isolated songorine from *Aconitum baicalensis* and evaluated its central anti-nociceptive effects in animal models [33]. Songorine demonstrated marked antinociceptive effects in an acetic acid induced cramp test that was antagonized by naloxones (opioid receptor nonselective antagonist) suggesting the existence of affinity for opioid receptors for antinociceptive like effect.

Also, the peripheral anti-inflammatory properties of songorine were confirmed using a carrageenan-induced inflammation assay [34]. Moreover, the compound also demonstrated marked anti-inflammatory effect following sub-plantar arachidonic acid injection. Most synthetic analgesic and anti-inflammatory drugs such as NSAIDS, are associated with gastrointestinal ulceration [35,36], but interestingly songorine was found to be free of gastrointestinal side effects and may, therefore, prove to be superior in efficacy and safety when compared to currently used analgesic and anti-inflammatory drugs. In this connection, new drug discovery approaches may consider it as a potential candidate for further detail studies.

The administration of natural compounds in arthritis and rheumatoid disorders has been increasingly evaluated as potent therapeutic options for these pathologies due to their wide availability, low costs and also minimal side effects. The observed anti-inflammatory properties often consist in downregulation of key cytokines like TNF- α and IFN- γ , but also inflammatory interleukins (IL-1 α /2/6/8/12). Increased evidences associates arthritis and rheumatoid disorders with elevated oxidative stress with consequences on the accumulation of oxidant and free radicals, whereby natural agents are potent inhibitors through their antioxidant properties. The proposed mechanisms consist in stimulation of antioxidant enzymes like SOD, catalase and GPx and also decrease of free radicals levels. Moreover, these beneficial roles are often completed by the ability of alkaloid compounds to counteract the activity of matrix metalloproteinases (MMPs) that normally are involved in matrix degradation (e.g., MMP-3, MMP-9) and are increasingly active in arthritis and rheumatoid conditions. Many of these pathologies are associated with pain and also disabilities caused in part by the increased amount of discomfort. Interestingly, some medicinal plants are also activating pathways being associated with pain alleviation and resulting analgesic and anti-nociceptive properties [37,38]. Songorine and also other natural drugs are emerging as potent alternatives for inflammatory and pain-causing disorders with minimal negative side effects. Even so, the restrictive number of clinical trials is partially impairing the recognition of these agents as therapeutic tools, since the majority of the experimental research is so far conducted on *in vitro* or *in vivo* models.

5. Mechanisms behind the increased wound healing properties of songorine (regenerative properties)

Zyuzkov and colleagues (2012) studied the regenerative effects of diverse diterpene alkaloids including songorine using a mouse skin wound model [39]. By day 3 after the wound infliction, songorine already showed significant regenerative action, and complete regeneration of the skin was observed by day 14 (for comparison, in the control animals the wounds healed by day 18 of the experiment). Songorine treatment reduced already by day 3 the leukocyte infiltration at the wound edges, derma, and in the underlying tissues. The underlying mechanism for this healing effect is thought being mediated by the profound action on resident precursor cells. Of the tested diterpene alkaloids, songorine was found to have the most prominent effect on wound healing. In a further study by the same group, treatment with songorine also increased the fibroblast content in the granulation layer using the same mouse skin wound model [40]. The addition of songorine *in vitro* to the culture medium results in a significant stimulation of mesenchymal precursor cells (CFU-F). The mechanism of action of this activation was

mediated by fibroblast growth factor (FGF) receptors, since the addition of anti-FGF receptor antibodies blocked this activation. Additional assays also evidenced that Inhibitors of PI3K, ERK1/2, and p38 interfere with the increase proliferative activity of mesenchymal progenitor cells associated with songorine treatment. ERK1/2 and p38 inhibitors also impeded cell differentiation [41]. The application of specific inhibitors of JNK and p53 enhanced stimulation of fibroblast colony/cluster formation and proliferative activity of mesenchymal precursor cells treated with songorine [41]. Further, mechanistic studies performed on NF- κ B/IKK-mediated signaling have demonstrated that toridonin, a NF- κ B inhibitor, prevents the proliferation and differentiation of mesenchymal progenitor cells induced by songorine treatment. Additionally, aurothiomalate, an IKK-2 blocker, inhibits the mitotic activity of fibroblast precursors without changing the rate of cell differentiation [23,42]. Finally, the same group also proved that adenylate cyclase also participates in the stimulation of proliferation of mesenchymal progenitor cells since its blockade leads to significant decrease of CFU-F [43]. Since songorine activates mesenchymal progenitor cell proliferation and differentiation, it is an attractive natural compound that may be used in future mesenchymal progenitor cell-based therapies.

6. *In vivo* pharmacokinetic studies involving songorine administration

In 2015, Dong et al. developed a novel quantification method evaluating the pharmacokinetics of songorine [44]. This simple method involves the use of ultra-performance liquid chromatography tandem mass spectrometry to analyze the pharmacokinetic properties of songorine in rat plasma. Following the intravenous administration of songorine at a concentration of 5 mg/kg, mean maximum plasma concentration was 654.79 ng/mL and the elimination half-life was 0.94 h. The initial rapid decline in the plasma concentration after songorine administration indicated that possibly the compound might have been distributed in various physiologic compartments beyond the plasma.

7. Aconite detoxification and safe administration of songorine

Aconite, a source of songorine, is well known for the beneficial effects of the related extracts, but also recognized as a toxic material that needs to be subjected to prior detoxification in order to be safe for human administration. For the moment, there are different purification methods, but even so, the workflow results in a significant loss of the active alkaloids with therapeutic value. A recent article demonstrated a new and improved method based on a one-step approach for detoxification that involves only cutting and drying of the compound [45]. Besides the major time parameters improving (10 h instead of days), there are also other advantages like high components percentages, quality consistency and also lack of heavy metals. Determination of the method superiority was done via HPLC and UHPLC/Q-TOF-MS quantifications and also multivariate analysis for product quality [45].

8. Conclusions and future prospects

Songorine is an aconitine alkaloid with notable pharmacological effects and promising preclinical potential. As such, it possesses antiarrhythmic, anti-anxiety, antinociceptive, anti-inflammatory properties as well as regenerative effects. The main limitation for its therapeutic use is the lack of clinical investigations that allow confirmation by promising results observed in animal models. Further evaluation of the mechanisms underlying these beneficial

properties and a detailed assessment of its safety profile are also required for a better assessment of its potential for future clinical applications.

Conflicts of interest

The authors declare that they have no competing financial interests.

Acknowledgments

A. G. Atanasov acknowledges the support by the Austrian Science Fund (FWF) project P25971-B23, and by the Polish KNOW (Leading National Research Centre) Scientific Consortium "Healthy Animal—Safe Food," decision of Ministry of Science and Higher Education No. 05-1/KNOW2/2015. A. Sureda was grant by the Programme of Promotion of Biomedical Research and Health Sciences CIBEROBN CB12/03/30038.

References

- [1] H. Khan, Medicinal plants in light of history recognized therapeutic modality, *J. Evidence-based Complementary Altern. Med.* 19 (2014) 216–219.
- [2] A.G. Atanasov, B. Waltenberger, E.-M. Pferschy-Wenzig, T. Linder, C. Wawrosch, P. Uhrin, V. Temml, L. Wang, S. Schwaiger, E.H. Heiss, Discovery and resupply of pharmacologically active plant-derived natural products: a review, *Biotechnol. Adv.* 33 (2015) 1582–1614.
- [3] Q. Aïn, H. Khan, M. Mubarak, A. Pervaiz, Plant alkaloids as antiplatelet agent: drugs of future in the light of recent development, *Front. Pharmacol.* 7 (2016) 292.
- [4] H. Khan, S. Khattak, Phyto-glycosides as therapeutic target in the treatment of diabetes, *Mini Rev. Med. Chem.* 17 (2016), <https://doi.org/10.2174/138955716666160909112751>. Accepted.
- [5] F. Maione, R. Russo, H. Khan, N. Mascolo, Medicinal plants with anti-inflammatory activities, *Nat. Prod. Res.* 30 (2016) 1343–1352.
- [6] Marya, H. Khan, Anti-inflammatory Potential of Alkaloids as a Promising Therapeutic Modality Letters in Drug Design and Discovery, 14, 2017, pp. 240–249.
- [7] S. Amin, H. Khan, Revival of natural products: utilization of modern technologies, *Curr. Bioact. Compd.* 12 (2016) 103–106.
- [8] H. Khan, M.A. Khan, A. Dullah, Antibacterial, antioxidant and cytotoxic studies of total saponin, alkaloid and sterols contents of decoction of Joshanda: identification of components identification through thin layer chromatography, *Toxicol. Industrial Health* 31 (2015) 202–208.
- [9] H. Khan, A. Murad, H. Iqbal, Enzyme inhibition activities of the extracts from rhizomes of Gloriosa superba Linn (Colchicaceae), *J. Enzyme Inhibition Med. Chem.* 22 (2008) 722–725.
- [10] H. Khan, S. Amin, ACE Inhibition of Plant Alkaloids. Targeted Approach for Selective Inhibition. Mini-reviews in Organic Chemistry Accepted, 2016.
- [11] V. Amirkia, M. Heinrich, Alkaloids as drug leads – a predictive structural and biodiversity-based analysis, *Phytochem. Lett.* 10 (2014) xviii–lii.
- [12] H. Khan, Alkaloids: potential therapeutic modality in the management of asthma, *J. Ayurvedic Herb. Med.* 1 (2015) 3.
- [13] S. Khattak, H. Khan, Anti-cancer potential phyto-alkaloids a Prospect. *Rev. Curr. Cancer Ther. Rev.* 12 (2016) 66–75.
- [14] A. Pervaiz, R. Khan, F. Anwar, M.A. Kamal, G. Mushtaq, H. Khan, Alkaloids: an emerging antibacterial modality against Methicillin Resistant *Staphylococcus aureus*, *Curr. Pharm. Des.* 22 (2016) 4420–4429.
- [15] S. Pervez, H. Khan, A. Pervaiz, Plant alkaloids as an emerging therapeutic alternative for the treatment of depression, *Front. Pharmacol.* 7 (2016).
- [16] S. Rehman, H. Khan, Advances in Antioxidant Potential of Natural Alkaloids. Current Bioactive Compounds Accepted, 2016.
- [17] X.-Y. Zhao, Y. Wang, Y. Li, X.-Q. Chen, H.-H. Yang, J.-M. Yue, G.-Y. Hu, Songorine, a diterpenoid alkaloid of the genus *Aconitum*, is a novel GABA A receptor antagonist in rat brain, *Neurosci. Lett.* 337 (2003) 33–36.
- [18] B. Jiang, S. Lin, C. Zhu, S. Wang, Y. Wang, M. Chen, J. Zhang, J. Hu, N. Chen, Y. Yang, Diterpenoid alkaloids from the lateral root of *Aconitum carmichaelii*, *J. Nat. Prod.* 75 (2012) 1145–1159.
- [19] A. Ameri, Inhibition of rat hippocampal excitability by the *Aconitum* alkaloid, 1-benzoylnapelline, but not by napelline, *Eur. J. Pharmacol.* 335 (1997) 145–152.
- [20] T. Okamoto, M. Natsume, Y. Itaka, A. Yoshino, T. Amiya, The Structure of luciduscine and the absolute configuration of songorine, *Chem. Pharm. Bull.* 13 (1965) 1270–1272.
- [21] H. Sun, M. Wang, A. Zhang, B. Ni, H. Dong, X. Wang, UPLC–Q–TOF–HDMs analysis of constituents in the root of two kinds of *aconitum* using a metabolomics approach, *Phytochem. Anal.* 24 (2013) 263–276.
- [22] A. Ameri, Effects of the *Aconitum* alkaloid songorine on synaptic transmission and paired-pulse facilitation of CA1 pyramidal cells in rat hippocampal slices, *Br. J. Pharmacol.* 125 (1998) 461–468.
- [23] G. Zyuz'kov, V. Zhdanov, L. Miroshnichenko, E. Udot, A. Chaikovskii, E. Simanina, M. Danilets, M.Y. Minakova, V. Udot, T. Tolstikova, Involvement of PI3K, MAPK ERK1/2 and p38 in functional stimulation of mesenchymal progenitor cells by alkaloid songorine, *Bull. Exp. Biol. Med.* 159 (2015) 58–63.
- [24] G. Zhou, L. Tang, X. Zhou, T. Wang, Z. Kou, Z. Wang, A review on phytochemistry and pharmacological activities of the processed lateral root of *Aconitum carmichaelii* Debeaux, *J. Ethnopharmacol.* 160 (2015) 173–193.
- [25] E. Nyirimigabo, Y. Xu, Y. Li, Y. Wang, K. Agyemang, Y. Zhang, A review on phytochemistry, pharmacology and toxicology studies of *Aconitum*, *J. Pharm. Pharmacol.* 67 (2015) 1–19.
- [26] F. Dzhakhangirov, M. Sultankhodzhaev, B. Tashkhodzhaev, B. Salimov, Diterpenoid alkaloids as a new class of antiarrhythmic agents. Structure-activity relationship, *Chem. Nat. Compd.* 33 (1997) 190–202.
- [27] B. Sagdullaev, A.Y. Abramov, A. Gagel'gans, F. Dzhakhangirov, P. Usmanov, Influence of a number of diterpene alkaloids on the calcium homeostasis of rat cardiomyocytes. Structure-activity relationship, *Chem. Nat. Compd.* 34 (1998) 480–483.
- [28] N.K. Shakhidoyatova, F. Dzhakhangirov, M. Sultankhodzhaev, Antiarrhythmic activity of diterpenoid alkaloids of the napelline type and their acylated derivatives, *Pharm. Chem. J.* 35 (2001) 266–267.
- [29] I. Tulyaganov, F. Dzhakhangirov, F. Sadritdinov, I. Khamadomov, Pharmacology of some aconite alkaloids, *Chem. Abstr.* 89 (1978) 140208.
- [30] A. Ameri, The effects of aconitum alkaloids on the central nervous system, *Prog. Neurobiol.* 56 (1998) 211–235.
- [31] M. Benn, J. Jacyno, *The Toxicology and Pharmacology of Diterpenoid Alkaloids. InAlkaloids, Chemical and Biological Perspectives*, John Wiley & Sons, New York, 1983.
- [32] Y.V. Nesterova, T. Povet'eva, N. Suslov, E. Shults, G. Zyuz'kov, S. Aksinenko, O. Afan'seva, A. Krapivin, T. Kharina, Anxiolytic activity of diterpene alkaloid songorine, *Bull. Exp. Biol. Med.* 159 (2015) 620–622.
- [33] Y.V. Nesterova, T. Povet'eva, N. Suslov, G. Zyuz'kov, S. Pushkarskii, S. Aksinenko, E. Schultz, S. Kravtsova, A. Krapivin, Analgesic activity of diterpene alkaloids from *Aconitum baicalensis*, *Bull. Exp. Biol. Med.* 157 (2014) 488.
- [34] Y.V. Nesterova, T. Povet'eva, N. Suslov, G. Zyuz'kov, S. Aksinenko, S. Pushkarskii, A. Krapivin, Anti-inflammatory activity of diterpene alkaloids from *aconitum baicalense*, *Bull. Exp. Biol. Med.* 156 (2014) 665–668.
- [35] A. Rauf, G. Uddin, B.S. Siddiqui, A. Khan, H. Khan, M. Arfan, N. Muhammad, A. Wadood, In-vivo antinociceptive, anti-inflammatory and antipyretic activity of pistagremic acid isolated from *Pistacia integerrima*, *Phytomedicine* 21 (2014) 1509–1515.
- [36] H. Khan, M.A. Khan, S. Hussain, R. Gaffar, N. Ashraf, In vivo antinociceptive and anticonvulsant activity of extracts of *Heliotropium strigosum*, *Toxicol. Industrial Health* 32 (2016) 860–865.
- [37] M.H. Farzaei, F. Farzaei, M. Gooshe, Z. Abbasabadi, N. Rezaei, A.H. Abdolghaffari, Potentially effective natural drugs in treatment for the most common rheumatic disorder: osteoarthritis, *Rheumatol. Int.* 35 (2015) 799–814.
- [38] M.H. Farzaei, F. Farzaei, M. Abdollahi, Z. Abbasabadi, A.H. Abdolghaffari, B. Mehraban, A mechanistic review on medicinal plants used for rheumatoid arthritis in traditional Persian medicine, *J. Pharm. Pharmacol.* 68 (2016) 1233–1248.
- [39] G. Zyuz'kov, A. Krapivin, Y.V. Nesterova, T. Povet'eva, V. Zhdanov, N. Suslov, T. Fomina, E. Udot, L. Miroshnichenko, E. Simanina, Mechanisms of regenerative effects of baikal aconite diterpene alkaloids, *Bull. Exp. Biol. Med.* 153 (2012) 847–851.
- [40] G. Zyuz'kov, A. Chaikovskii, A. Ligacheva, V. Zhdanov, E. Udot, M. Danilets, L. Miroshnichenko, E. Simanina, N. Suslov, E. Losev, Role of receptors to fibroblast growth factor (FGF) on mesenchymal precursor cells in the realization of regenerative effects of alkaloid songorine, *Bull. Exp. Biol. Med.* 157 (2014) 146.
- [41] G. Zyuz'kov, V. Zhdanov, E. Udot, L. Miroshnichenko, A. Chaikovskii, E. Simanina, V. Udot, L. Stavrova, T.Y. Polyakova, M.Y. Minakova, Role of JNK and involvement of p53 in stimulation of growth potential realization of mesenchymal precursor cells by alkaloid songorine, *Bull. Exp. Biol. Med.* 160 (2015) 64–67.
- [42] G. Zyuz'kov, V. Zhdanov, E. Udot, L. Miroshnichenko, A. Chaikovskii, E. Simanina, M. Danilets, M.Y. Minakova, V. Demkin, V. Udot, Role of NF-[kappa]B/IKK-Dependent signaling in functional stimulation of mesenchymal progenitor cells by alkaloid songorine, *Bull. Exp. Biol. Med.* 158 (2015) 624–627.
- [43] G. Zyuz'kov, V. Zhdanov, E. Udot, L. Miroshnichenko, A. Chaikovskii, E. Simanina, T.Y. Polyakova, M.Y. Minakova, V. Udot, T. Tolstikova, Role of cAMP and IKK-2-dependent signaling pathways in functional stimulation of mesenchymal progenitor cells with alkaloid songorine, *Bull. Exp. Biol. Med.* 159 (2015) 642.
- [44] Y.-y. Dong, B. Mao, H. Guan, Y. Bai, B. Chi, Y.-y. Shan, Q.-q. Lian, R.-s. Ge, Determination of songorine in rat plasma by UPLC–MS/MS: assay development and application to pharmacokinetic study, *J. Chromatography B* 1002 (2015) 234–238.
- [45] D.-K. Zhang, H. Xue, T. Peng, L. Rui-Yu, N. Ming, C.-E. Zhang, W. Jia-Bo, Y. Ming, X. Xiao-He, Establishment of one-step approach to detoxification of hyper-toxic aconite based on the evaluation of alkaloids contents and quality, *Chin. J. Nat. Med.* 15 (2017) 49–61.